
ACS Omega, Journal Year: 2024, Volume and Issue: 10(1), P. 848 - 861
Published: Dec. 25, 2024
Currently, available therapies for diabetes cannot achieve normal sugar values in a high percentage of treated patients. This work synthesized series carbazole-triazole-thione derivatives, and their potential antidiabetic activity was investigated against the key diabetic enzymes α-amylase glycosidase. Normal human hepatic stellate cells (LX-2) were employed to assess cytotoxicity safety, followed by vivo testing investigate hypoglycemic effect most promising agent. As result, set 18 carbazole-1,2,4-triazole-thione derivatives synthesized. Seven structures demonstrated inhibitory enzyme, with IC50 lower than 6.4 μM. Among them, compounds C5f, C5o, C5r exhibited highest potency, 0.56, 0.53, 0.97 μM, respectively, compared well-known inhibitor acarbose, which has an value 5.31 Exploring inhibition potency these α-glucosidase enzyme revealed that C5f act as moderate inhibitors, 11.03 13.76 respectively. Moreover, at 100 μM concentration, evaluated showed negligible cytotoxic LX-2 cell lines, particularly C5o C5s, 3-fold positive control 5-Flururicle (cell viability 13.45%). Thus, compound selected evaluation, after administering five doses this (10 mg/kg) group III mice, significant reduction glucose concentration observed, bringing it down from 290.54 216.15 mg/dL, comparison did not show blood level. These observed vitro results upheld performing chemoinformatic studies elucidated binding interactions active within enzyme's site highlighted critical roles both 1,2,4-triazole-3-thione carbazole scaffolds interactions. Finally, drug-likeness profiles our suggest candidates further clinical trials.
Language: Английский